Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer

Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer

<p>Abstract</p> <p>Background</p> <p>Erlotinib is a Human Epidermal Growth Factor Receptor Type 1/tyrosine kinase (EGFR) inhibitor which is used for non-small-cell lung cancer treatment. Despite that erlotinib is considered to have a favorable safety profile, adverse ev...

Full description

Bibliographic Details
Main Authors:	Colin Guillaume, Copin Marie, Scherpereel Arnaud, Makris Demosthenes, Brun Luc, Lafitte Jean, Marquette Charles
Format:	Article
Language:	English
Published:	BMC 2007-08-01
Series:	BMC Cancer
Online Access:	http://www.biomedcentral.com/1471-2407/7/150

Similar Items

Erlotinib induced fatal interstitial lung disease in a patient with metastatic non-small cell lung cancer: case report and review of literature
by: Ankit Mangla, et al.
Published: (2016-10-01)

Four Cases of Interstitial Lung Disease Induced by Erlotinib  and A Review of the Literatures
by: Xiaoling WU, et al.
Published: (2012-08-01)

Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease
by: Molly S.C. Li, M.B.B.S., et al.
Published: (2024-04-01)

Serum biomarkers in interstitial lung diseases
by: Anevlavis Stavros, et al.
Published: (2005-07-01)

Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer.
by: Jasmine G Lee, et al.
Published: (2012-01-01)

Acute Fatal Liver Toxicity under Erlotinib
by: Sabina Schacher-Kaufmann, et al.
Published: (2010-06-01)

Fatal rapidly progressive interstitial lung disease in a patient with amyopathic dermatomyositis
by: Abdullah Mobeireek, et al.
Published: (2021-01-01)

Endotyping of progressive fibrotic interstitial lung diseases: It is the final destination that matters and not the journey
by: Argyris Tzouvelekis, et al.
Published: (2020-01-01)

Angiogenesis in Interstitial Lung Diseases: a pathogenetic hallmark or a bystander?
by: Anevlavis Stavros, et al.
Published: (2006-05-01)

The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma
by: Atakan Topcu, et al.
Published: (2022-10-01)

Prolonged response to first-line erlotinib for advanced lung adenocarcinoma
by: Copeman Michael
Published: (2008-11-01)

Experience with erlotinib in the treatment of non-small cell lung cancer
by: Lorenza Landi, et al.
Published: (2015-08-01)

Erlotinib resistance in Lung Cancer: Current Progress and Future Perspectives
by: Joy eTang, et al.
Published: (2013-02-01)

Erlotinib for the treatment of relapsed non-small cell lung cancer
by: C McLeod, et al.
Published: (2009-06-01)

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
by: William Pao, et al.
Published: (2005-01-01)

Sartan-induced interstitial lung disease
by: Caroline Dahlqvist, et al.
Published: (2023-01-01)

Erlotinib-Loaded Dendrimer Nanocomposites as a Targeted Lung Cancer Chemotherapy
by: Wafa K. Fatani, et al.
Published: (2023-05-01)

Effects of Erlotinib on 34 Patients with Advanced Squamous Cell Lung Cancer
by: Fang CHENG, et al.
Published: (2016-10-01)

Lung transplantation for interstitial lung disease
by: Siddhartha G. Kapnadak, et al.
Published: (2021-08-01)

Bridges of Pulmonology 2023 proceedings: Highlights in the field of interstitial lung diseases
by: Vasilina Sotiropoulou, et al.
Published: (2024-03-01)

Interstitial lung disease
by: Vincent Cottin
Published: (2013-03-01)

Interstitial lung disease
by: Katerina M. Antoniou, et al.
Published: (2014-03-01)

Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormality
by: Qian Zhou, et al.
Published: (2023-03-01)

A Novel STAT3 Gain-of-Function Mutation in Fatal Infancy-Onset Interstitial Lung Disease
by: Mengyue Deng, et al.
Published: (2022-05-01)

Erythematous auricular papules in the fatal cases of anti-MDA5 antibody-positive interstitial lung disease
by: Porntip Intapiboon, et al.
Published: (2020-01-01)

Lung Ultrasound in Diagnosis of Interstitial Lung Disease
by: Sagun Manandhar
Published: (2023-07-01)

Erlotinib in combined therapy of common lung adenocarcinoma in the presence of EGFR gene mutation
by: S. V. Orlov, et al.
Published: (2019-06-01)

Vorinostat enhances the therapeutic potential of Erlotinib via MAPK in lung cancer cells
by: Amany I Alqosaibi, et al.
Published: (2022-01-01)

A Systematic Review of Erlotinib for Advanced Non-small Cell Lung Cancer
by: Jinhui TIAN, et al.
Published: (2009-12-01)

The Analysis of Erlotinib on Brain Metastases in Patients with Non-small-cell Lung Cancer
by: Baohui HAN, et al.
Published: (2009-12-01)

Rapid regression of choroidal metastasis from lung cancer using erlotinib (Tarceva)
by: Xuemei Ye, et al.
Published: (2014-01-01)

Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians
by: Yongsheng Wang, et al.
Published: (2012-01-01)

Acute Generalized Exanthematous Pustulosis Caused by Erlotinib in a Patient with Lung Cancer
by: Natsuko Komiya, et al.
Published: (2021-03-01)

VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II study
by: Thierry Berghmans, et al.
Published: (2015-10-01)

Interstitial Lung Disease Associated with Lung Cancer Treatment
by: Zhiwei CAO, et al.
Published: (2013-05-01)

Telomeres in Interstitial Lung Disease
by: Carmel J. W. Stock, et al.
Published: (2021-03-01)

Oxygen in interstitial lung diseases
by: Ricardo Cordeiro, et al.
Published: (2023-03-01)

Interstitial lung diseases in children
by: N. S. Lev, et al.
Published: (2016-03-01)

34 Interstitial lung disease
by: Vanessa Smith
Published: (2023-09-01)

Hydrodynamics of the lung interstitial space.
by: A. Sales Luís
Published: (1980-12-01)